Celgene (NASDAQ:CELG)‘s stock had its “top pick” rating reaffirmed by equities research analysts at Royal Bank of Canada in a report released on Tuesday.
Other research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the company a “hold” rating in a report on Tuesday. BTIG Research reiterated a “hold” rating on shares of Celgene in a report on Tuesday. UBS Group lowered shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective for the company. in a report on Thursday, October 26th. BMO Capital Markets dropped their price objective on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $162.00 to $136.00 in a research report on Friday, October 20th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $129.98.
Shares of Celgene (CELG) traded up $0.26 during midday trading on Tuesday, reaching $102.91. 12,934,200 shares of the company were exchanged, compared to its average volume of 8,453,729. The company has a market cap of $83,020.00, a price-to-earnings ratio of 24.27, a PEG ratio of 0.65 and a beta of 1.77. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $1.58 EPS. analysts predict that Celgene will post 6.71 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the period. Vanguard Group Inc. lifted its stake in Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares in the last quarter. Jennison Associates LLC lifted its stake in Celgene by 11.5% during the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after acquiring an additional 1,546,673 shares in the last quarter. FMR LLC lifted its stake in Celgene by 5.9% during the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after acquiring an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Celgene by 3.3% during the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock valued at $1,439,025,000 after acquiring an additional 349,974 shares in the last quarter. 79.54% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Royal Bank of Canada Reiterates Top Pick Rating for Celgene (CELG)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/23/royal-bank-of-canada-reiterates-top-pick-rating-for-celgene-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.